Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity.

Chen H, Beardsley GP, Coen DM.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17462-7. doi: 10.1073/pnas.1405981111. Epub 2014 Nov 24.

2.

Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.

Xu L, Chong Y, Hwang I, D'Onofrio A, Amore K, Beardsley GP, Li C, Olson AJ, Boger DL, Wilson IA.

J Biol Chem. 2007 Apr 27;282(17):13033-46. Epub 2007 Feb 26.

3.

Crystal structures of human bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase/IMP cyclohydrolase in complex with potent sulfonyl-containing antifolates.

Cheong CG, Wolan DW, Greasley SE, Horton PA, Beardsley GP, Wilson IA.

J Biol Chem. 2004 Apr 23;279(17):18034-45. Epub 2004 Feb 13.

5.

Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.

Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B.

Clin Cancer Res. 2003 Nov 15;9(15):5442-53. Review.

6.

Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.

Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, Bernstein M, Beardsley GP, Krailo MD, Devidas M, Bertino JR, Meyers PA, Gorlick R.

Clin Cancer Res. 2003 Feb;9(2):837-44.

7.

Structural insights into the avian AICAR transformylase mechanism.

Wolan DW, Greasley SE, Beardsley GP, Wilson IA.

Biochemistry. 2002 Dec 31;41(52):15505-13.

PMID:
12501179
8.

Crystal structures of human GAR Tfase at low and high pH and with substrate beta-GAR.

Zhang Y, Desharnais J, Greasley SE, Beardsley GP, Boger DL, Wilson IA.

Biochemistry. 2002 Dec 3;41(48):14206-15.

PMID:
12450384
9.

10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.

Marsilje TH, Labroli MA, Hedrick MP, Jin Q, Desharnais J, Baker SJ, Gooljarsingh LT, Ramcharan J, Tavassoli A, Zhang Y, Wilson IA, Beardsley GP, Benkovic SJ, Boger DL.

Bioorg Med Chem. 2002 Aug;10(8):2739-49.

PMID:
12057663
11.

Crystal structure of a bifunctional transformylase and cyclohydrolase enzyme in purine biosynthesis.

Greasley SE, Horton P, Ramcharan J, Beardsley GP, Benkovic SJ, Wilson IA.

Nat Struct Biol. 2001 May;8(5):402-6.

PMID:
11323713
13.
14.

Dihydrofolate reductase from Kaposi's sarcoma-associated herpesvirus.

Cinquina CC, Grogan E, Sun R, Lin SF, Beardsley GP, Miller G.

Virology. 2000 Mar 1;268(1):201-17.

15.

Expression of HER2/erbB-2 correlates with survival in osteosarcoma.

Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA.

J Clin Oncol. 1999 Sep;17(9):2781-8.

PMID:
10561353
16.

Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

Whitehead VM, Vuchich MJ, Cooley LD, Lauer SJ, Mahoney DH, Shuster JJ, Payment C, Koch PA, Akabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Look AT, Beardsley GP, Pullen DJ, Camitta B.

Leuk Lymphoma. 1998 Nov;31(5-6):507-19.

PMID:
9922041
17.

Structure and functional relationships in human pur H.

Beardsley GP, Rayl EA, Gunn K, Moroson BA, Seow H, Anderson KS, Vergis J, Fleming K, Worland S, Condon B, Davies J.

Adv Exp Med Biol. 1998;431:221-6.

PMID:
9598063
18.

Solution structure of a DNA decamer containing the antiviral drug ganciclovir: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement.

Foti M, Marshalko S, Schurter E, Kumar S, Beardsley GP, Schweitzer BI.

Biochemistry. 1997 May 6;36(18):5336-45.

PMID:
9154915
19.

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM.

Cancer Res. 1997 Mar 15;57(6):1116-23.

22.

Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.

Pizzorno G, Moroson BA, Cashmore AR, Russello O, Mayer JR, Galivan J, Bunni MA, Priest DG, Beardsley GP.

Cancer Res. 1995 Feb 1;55(3):566-73.

23.
24.
26.

5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines.

Pizzorno G, Cashmore AR, Moroson BA, Cross AD, Smith AK, Marling-Cason M, Kamen BA, Beardsley GP.

J Biol Chem. 1993 Jan 15;268(2):1017-23.

27.

Altered transport of folic acid and antifolates through the carrier mediated reduced folate transport system in a human leukemia cell line resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF).

Pavlovic M, Leffert JJ, Russello O, Bunni MA, Beardsley GP, Priest DG, Pizzorno G.

Adv Exp Med Biol. 1993;338:775-8. No abstract available.

PMID:
8304227
28.

Gowland Hopkins Lectureship. Edward C. Taylor.

Beardsley GP.

Adv Exp Med Biol. 1993;338:vii-viii. No abstract available.

PMID:
8304088
30.

A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.

Vats T, Buchanan G, Mehta P, Ragab A, Hvizdale E, Nitschke R, Link M, Beardsley GP, Maybee D, Krischer J.

Invest New Drugs. 1992 Aug;10(3):231-4.

PMID:
1428733
31.

Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.

Rosowsky A, Galivan J, Beardsley GP, Bader H, O'Connor BM, Russello O, Moroson BA, DeYarman MT, Kerwar SS, Freisheim JH.

Cancer Res. 1992 Apr 15;52(8):2148-55.

32.
33.

Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.

Sokoloski JA, Beardsley GP, Sartorelli AC.

Cancer Chemother Pharmacol. 1991;28(1):39-44.

PMID:
2040032
34.

Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines.

Pizzorno G, Sokoloski JA, Cashmore AR, Moroson BA, Cross AD, Beardsley GP.

Mol Pharmacol. 1991 Jan;39(1):85-9.

PMID:
1702876
35.

Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.

Sokoloski JA, Beardsley GP, Sartorelli AC.

Cancer Res. 1989 Sep 1;49(17):4824-8.

36.

Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues.

Taylor EC, Hamby JM, Shih C, Grindey GB, Rinzel SM, Beardsley GP, Moran RG.

J Med Chem. 1989 Jul;32(7):1517-22.

PMID:
2738886
37.
38.

A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.

Beardsley GP, Moroson BA, Taylor EC, Moran RG.

J Biol Chem. 1989 Jan 5;264(1):328-33.

39.

Mechanism of the induction of the differentiation of HL-60 leukemia cells by antifolates.

Sokoloski JA, Beardsley GP, Sartorelli AC.

Cancer Commun. 1989;1(3):199-207.

PMID:
2700913
40.

Chemical synthesis of DNA oligomers containing cytosine arabinoside.

Beardsley GP, Mikita T, Klaus MM, Nussbaum AL.

Nucleic Acids Res. 1988 Oct 11;16(19):9165-76.

41.

Functional consequences of the arabinosylcytosine structural lesion in DNA.

Mikita T, Beardsley GP.

Biochemistry. 1988 Jun 28;27(13):4698-705.

PMID:
2458756
42.

2',3'-Dideoxyadenosine is selectively toxic for TdT-positive cells.

Spigelman Z, Duff R, Beardsley GP, Broder S, Cooney D, Landau NR, Mitsuya H, Ullman B, McCaffrey R.

Blood. 1988 Jun;71(6):1601-8.

PMID:
2836001
43.

Novel blunt-end addition reactions catalyzed by DNA polymerase I of Escherichia coli.

Clark JM, Joyce CM, Beardsley GP.

J Mol Biol. 1987 Nov 5;198(1):123-7.

PMID:
3323527
44.

Modeling and molecular mechanical studies of the cis-thymine glycol radiation damage lesion in DNA.

Clark JM, Pattabiraman N, Jarvis W, Beardsley GP.

Biochemistry. 1987 Aug 25;26(17):5404-9.

PMID:
3676260
45.

Functional effects of cis-thymine glycol lesions on DNA synthesis in vitro.

Clark JM, Beardsley GP.

Biochemistry. 1987 Aug 25;26(17):5398-403.

PMID:
3676259
46.

Chemical consequences of incorporation of 5-fluorouracil into DNA as studied by NMR.

Kremer AB, Mikita T, Beardsley GP.

Biochemistry. 1987 Jan 27;26(2):391-7.

PMID:
3828314
47.

Thymine glycol lesions terminate chain elongation by DNA polymerase I in vitro.

Clark JM, Beardsley GP.

Nucleic Acids Res. 1986 Jan 24;14(2):737-49.

48.
49.

Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.

Taylor EC, Harrington PJ, Fletcher SR, Beardsley GP, Moran RG.

J Med Chem. 1985 Jul;28(7):914-21.

PMID:
4009615
50.

Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis.

Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Miller BA, Nathan DG.

J Clin Invest. 1985 Jun;75(6):1999-2005.

Supplemental Content

Loading ...
Support Center